Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 11/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.65 |
| ▸ | PHLPP1 | O60346 | 3/20 | 0.65 |
| ▸ | ILK | Q13418 | 3/20 | 0.65 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.55 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14580950 | 0.84 | AKT1 (0.70) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL18212526 | 0.84 | AKT1 (0.70) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5771546 | 0.84 | AKT1 (0.70) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5771699 | 0.83 | AKT1 (0.69) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL19659847 | 0.82 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL5441388 | 0.82 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL4677441 | 0.82 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL3270839 | 0.82 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL29393858 | 0.82 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 | |
| SCHEMBL407517 | 0.82 | AKT1 (0.65) | AKT1PDPK1PHLPP1ILKALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392639-B1 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1392639-A4 | PYRUVATE DERIVATIVES | GALILEO LAB INC (US) | 2006-01-25 | — | — | EP | disclosed |
| US-6916850-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-6900218-B2 | Pyruvate derivatives | GALILEO PHARMACEUTICALS, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1392639-A1 | PYRUVATE DERIVATIVES | Galileo Laboratories, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030013846-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013656-A1 | Pyruvate derivatives | ALLOY VENTURES, INC. | 2003-01-16 | — | — | US | disclosed |
| US-20030013847-A1 | Cytoprotective agents | MONSANTO TECHNOLOGY LLC | 2003-01-16 | — | — | US | disclosed |
| US-20030013657-A1 | Pyruvate derivatives | MONSANTO TECHNOLOGY, LLC. | 2003-01-16 | — | — | US | disclosed |
| WO-2002090314-A1 | PYRUVATE DERIVATIVES | GALILEO LABORATORIES, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013847-A1 | Cytoprotective agents | PC, PDK1, PDK2 | AKT1 1499/4885PDPK1 285/4885PHLPP1 2393/4885 |
| US-20030013657-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | AKT1 2003/4885PDPK1 249/4885PHLPP1 3347/4885 |
| US-20030013846-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | AKT1 2003/4885PDPK1 249/4885PHLPP1 3347/4885 |
| US-20030013656-A1 | Pyruvate derivatives | PC, PDK1, PDK4 | AKT1 2003/4885PDPK1 249/4885PHLPP1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.